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Abstract: Long-term outcome of percutaneous coronary intervention (PCI) compared to 
coronary artery bypass grafting (CABG) for unprotected left main coronary artery disease 
(ULMCAD) remain to be investigated. We identified 1005 patients with ULMCAD among 
15939 patients with first coronary revascularization enrolled in the CREDO-Kyoto PCI/CABG 
registry cohort-2. Cumulative 3-year incidence of a composite of death/myocardial infarction 
(MI)/stroke was significantly higher in the PCI group than in the CABG group (22.7% vs. 
14.8%, log rank p=0.0006). However, the adjusted outcome was not different between the PCI 
and CABG groups (hazard ratio (HR): 1.30, 95% confidence interval (C.I): 0.79-2.15, p=0.30). 
The stratified analysis using the SYNTAX score demonstrated that risk for a composite of 
death/MI/stroke was not different between the 2 treatment groups in patients with low (<23) and 
intermediate SYNTAX score (23-33) (adjusted HR 1.70, 95% CI: 0.77-3.76, p=0.19 and 
adjusted HR 0.86, 95% CI: 0.37-1.99, p=0.72, respectively), while in patients with high 
SYNTAX score (≥ 33), it was significantly higher after PCI than after CABG (adjusted HR 2.61, 
95% CI: 1.32-5.16, p=0.006). In conclusions, the risk of PCI for serious adverse events seemed 
to be comparable to that after CABG in ULMCAD patients with low or intermediate SYNTAX 
score, while PCI as compared with CABG was associated with a higher risk for serious adverse 
events in patients with high SYNTAX score. 




In recent years, several observational studies reported favorable clinical outcomes of 
percutaneous coronary intervention (PCI) using drug eluting stent (DES) in patients with 
unprotected left main coronary artery disease (ULMCAD) 1-3. SYNTAX (Synergy Between 
Percutaneous Coronary Intervention With Taxus and Cardiac Surgery) randomized trial reported 
comparable safety and efficacy outcomes of PCI relative to coronary artery bypass grafting 
(CABG) in the left main disease subset4-6. Reflecting these study results, updated clinical 
guidelines for ULMCAD regarded PCI as an alternative to CABG in patients with less complex 
coronary anatomy or in patients with high surgical risk7, 8. However, number of patients enrolled 
in these trials was still insufficient in drawing definitive conclusions on the role of PCI in 
treating patients with ULMCAD. Therefore, we evaluated the long-term clinical outcome of 
PCI relative to CABG and the utility of the SYNTAX score for risk stratification in patients 
with ULMCAD in a large observational database in Japan.  
Methods 
      The CREDO-Kyoto (Coronary REvascularization Demonstrating Outcome Study in 
Kyoto) PCI/CABG registry cohort-2 is a physician-initiated, non-company sponsored, 
multi-center registry that enrolled consecutive patients undergoing first coronary 
revascularization among 26 centers in Japan between January 2005 and December 2007. The 
4 
 
relevant ethics committees in all 26 participating centers (Supplemental Appendix A) approved 
the research protocol. Because of retrospective enrollment, written informed consents from the 
patients were waived. However, patients who refused participation in the study when contacted 
for follow-up were excluded.  
The study design and patient enrollment in the registry have been described in detail 
previously9. Among 15939 patients enrolled in the registry, the study population for the current 
pre-specified sub-analysis of the CREDO-Kyoto PCI/CABG registry cohort-2 consisted of 1005 
patients with ULMCAD (PCI: 365 patients, and CABG: 640 patients), excluding those patients 
with refusal for study participation, concomitant non-coronary surgery and acute myocardial 
infarction (Figure 1).  
Demographic, angiographic, and procedural data were collected from hospital charts 
according to pre-specified definitions by experienced research coordinators in the independent 
research organization (Research Institute for Production Development, Kyoto, Japan) 
(Supplemental Appendix B). Patients with ULMCAD were identified using the angiographic 
information recorded in their hospital charts. Therefore, the current study population included 
those patients in whom PCI was not attempted for the left main coronary artery lesions based on 




The SYNTAX score was calculated using the SYNTAX score calculator (available at 
http://www.syntaxscore.com) by a dedicated SYNTAX score committee (Supplemental 
Appendix C) in a blinded fashion to the clinical data. Intra- and inter-observer variabilities of 
the SYNTAX score calculation in our group were previously reported10. The cutoff values for 
the SYNTAX score tertiles (low-score: <23, intermediate-score: 23-33, and high-score: ≥33) 
were defined according to the analysis in the SYNTAX trial4, 5.  
     The primary outcome measure for the current analysis was defined as a composite of 
all-cause death, myocardial infarction (MI), and stroke. Other pre-specified endpoints included 
all-cause death, cardiac death, MI, stroke, and coronary revascularization. Death was regarded 
as cardiac in origin unless obvious non-cardiac causes could be identified. Any death during the 
index hospitalization for coronary revascularization was regarded as cardiac death. MI was 
defined according to the definition in the Arterial Revascularization Therapy Study11. Stroke 
was defined as ischemic or hemorrhagic stroke requiring hospitalization with symptoms lasting 
>24 hours. Coronary revascularization was defined as either PCI or CABG for any reasons. 
Scheduled staged coronary revascularization procedures performed within 3 months of the 




 Collection of follow-up information was mainly conducted through review of 
inpatient and outpatient hospital charts by the clinical research coordinators in the independent 
research organization. Additional follow-up information was collected through contact with 
patients, relatives and/or referring physicians by sending mail with questions regarding vital 
status, additional hospitalizations, and status of antiplatelet therapy. Death, MI, stent thrombosis 
(ST), and stroke were adjudicated by the clinical event committee (Supplemental Appendix D).  
Since final data collection for follow-up events was initiated on July 1st, 2009, 
follow-up events were censored on this date. Median follow-up duration for surviving patients 
was 1027 (inter-quartile range [IQR]: 734-1311) days. Complete 1-year follow-up information 
was obtained in 95.4% of patients (96.4% in the PCI group and 94.8% in the CABG group: 
p=0.24).  
      Categorical variables were presented as number and percentage and were compared with 
the chi-square test. Continuous variables were expressed as mean value ± standard deviation 
(SD) or median with Interquartile range (IQR). Continuous variables were compared using the 
Student’s t-test or Wilcoxon rank sum test based on their distributions.  
      Cumulative incidence was estimated by the Kaplan-Meier method and differences were 
assessed using the log-rank test. The effects of PCI relative to CABG for individual endpoints 
were expressed as hazard ratios (HR) with 95% confidence intervals (CI). In the entire study 
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population, HR was estimated using the non-parsimonious multivariable Cox proportional 
hazard models adjusted for the 30 clinically relevant factors in Table 1, which was consistent 
with previous reports from the current registry. Continuous variables were dichotomized using 
clinically meaningful reference values or median values. Proportional hazard assumptions for 
potential independent risk-adjusting variables were assessed on log (time) versus log [-log 
(survival)] plots stratified by the variable, and the assumptions were verified as acceptable for 
all variables. We incorporated the 26 participating centers in the Cox proportional hazard 
models as the stratification variable. 
The unadjusted and adjusted risks of PCI relative to CABG for the primary outcome 
measure were evaluated in each SYNTAX score category as a subgroup analysis to assess 
utility of the SYNTAX score for risk stratification. In addition to the modes of coronary 
revascularization (PCI versus CABG), 4 variables with p value <0.05 in the previously 
described full model (Age >= 75 years, Estimated glomerular filtration rate <30 mL/min/1.73m2, 
without hemodialysis, Hemodialysis, and Proton pump inhibitors) were included in the 
multivariable models for the subgroup analysis reflecting our preference for parsimonious 
models to avoid over-fitting.  
Statistical analyses were conducted by a physician (Shiomi H) and a statistician 
(Morimoto T) using the JMP 8.0 (SAS Institute Inc, Cary, NC) software and SAS 9.2 (SAS 
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Institute Inc, Cary, NC) statistical analysis software. All the statistical analyses were two-tailed 
and p values <0.05 were considered statistically significant. 
Results 
      Patients in the PCI group were older, and more often had malignancy and severe mitral 
regurgitation, while patients in the CABG group more often had diabetes on insulin therapy, and 
thrombocytopenia (Table 1).  
      The CABG group included more patients with complex coronary anatomy and greater 
numbers of target lesions or anastomoses (Table 1). The SYNTAX scores were available in 932 
patients (92.7%). The median SYNTAX score was significantly greater in the CABG group 
than in the PCI group. Stents were used in 98% of the patients in the PCI group, and at least one 
DES was used in 78% of the patients. In the PCI group, PCI targeting for ULMCA lesion was 
performed in 306 patients (83.4%), in whom left main distal bifurcation was involved in 210 
patients (68.6%) and DES was used for the left main lesion in 209 patients (68.3%). At least one 
internal thoracic artery was used in 98.3% of patients in the CABG group, and the prevalence of 
off-pump CABG was high (64.7%). Baseline medications were significantly different in several 
aspects between the two groups (Table 1). 
 The cumulative 3-year incidence of the primary outcome measure (death/MI/stroke) 
in the PCI group was significantly higher than that in the CABG group (22.7% vs. 14.8%, log 
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rank p=0.0006) (Figure 2A). However, after adjusting for potential confounders, the risk of PCI 
relative to CABG for the primary outcome measure was not significantly different (adjusted 
HR: 1.30, 95% C.I: 0.79-2.15, p=0.30) (Table 2). Regarding survival outcome, the cumulative 
3-year incidence of all-cause death and cardiac death were higher in the PCI group than that in 
the CABG group (13.6% vs. 9.2%, log rank p=0.01, and 7.4% vs. 3.7%, log rank p=0.005, 
respectively) (Figure 2B, and 2C). However, the adjusted risk for all-cause death and cardiac 
death were not different between the 2 groups (adjusted HR: 0.79, 95% C.I: 0.40-1.57, p=0.50, 
and adjusted HR: 1.80, 95% C.I: 0.64-5.09, p=0.27, respectively) (Table 2). The cumulative 
3-year incidence of MI was significantly higher in the PCI group compared to the CABG group 
(5.5% vs. 2.3%, log rank p=0.003) (Figure 2D). However, the adjusted risk of PCI relative to 
CABG for MI was not significantly different (adjusted HR: 2.47, 95% C.I: 0.81-7.54, p=0.11), 
although the point estimate strongly favored CABG (Table 2). The cumulative 3-year incidence 
of definite ST in the PCI group was low (1.5%). The risk for stroke was not different between 
the two groups (6.6% vs. 5.5%, log rank p=0.43, adjusted HR: 0.79, 95% C.I: 0.30-2.08, 
p=0.63) (Figure 2E, and Table 2). PCI was associated with a markedly higher risk for any 
coronary revascularization compared to CABG (43.4% vs. 11.2%, log rank p<0.0001, adjusted 
HR: 5.83, 95% C.I: 3.74-9.09, p<0.0001) (Figure 2F, and Table 2).  
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Clinical outcome was compared between the PCI and CABG groups among the 3 
categories of coronary anatomic complexities stratified by the SYNTAX score. The cumulative 
3-year incidences of the primary outcome measure were not different between the PCI and 
CABG groups in patients with low and intermediate SYNTAX score (22.8% vs. 14.7%, log 
rank p=0.08, and 19.5% vs. 14.3%, log rank p=0.21). However, the cumulative 3-year incidence 
of the primary outcome measure was markedly higher in the PCI group than that in the CABG 
group in patients with high SYNTAX score (27.4% vs. 16.8%, log rank p=0.006) (Figure 3). 
After adjustment for potential confounders, the risk of PCI relative to CABG for the primary 
outcome measure remained significantly higher in patients with high SYNTAX score (adjusted 
HR: 2.61, 95% C.I: 1.32-5.16, p=0.006), while it was not significantly different in patients with 
low and intermediate SYNTAX score (adjusted HR: 1.70, 95% C.I: 0.77-3.76, p=0.19, and 
adjusted HR: 0.86, 95% C.I: 0.37-1.99, p=0.72). 
Discussion 
 The main findings in the current study were as follows; (1) the 3-year clinical 
outcome of PCI was comparable with that of CABG in terms of serious cardiovascular events in 
patients with ULMCAD; (2) the risk for serious cardiovascular events was not significantly 
different between PCI and CABG in patients with low or intermediate SYNTAX score, while it 
was markedly higher after PCI as compared with CABG in patients with high SYNTAX score.   
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 The favorable outcome of PCI for the treatment of ULMCAD as demonstrated in the 
left main subset of the SYNTAX trial, led to the recently updated recommendation of PCI for 
ULMCAD1-6. However, evidence from randomized trials comparing PCI using DES with 
CABG in patients with ULMCAD is quite limited. Indeed, Boudriot et al. failed to demonstrate 
non-inferiority of PCI using SES relative to CABG with respect to major adverse cardiac events 
in patients with ULMCAD in their randomized trial, while Park et al. showed non-inferiority of 
PCI relative to CABG with respect to MACCE in the PRECOMBAT Trial12, 13. Moreover, the 
results from randomized trials should be interpreted cautiously for application to daily clinical 
practice because selected patients with relatively low risk profiles were generally enrolled in the 
randomized trials. Therefore, the results from large-scale observational studies are also 
important. The current analysis from a multicenter registry in Japan suggested comparable 
long-term clinical outcome in terms of a composite of death/MI/stroke between PCI and CABG 
in patients with ULMCAD, which is consistent with previous observational studies as well as 
SYNTAX and PRECOMBAT randomized trials1, 4-6, 13, 14.  
 The appropriate selection of patients with ULMCAD for PCI is the most important 
consideration while expanding the use of PCI for ULMCAD. Risk stratification using the 
SYNTAX score has drawn attention for the selection of revascularization procedures in 
complex coronary artery disease, such as ULMCAD or triple vessel coronary artery disease4. 
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However, the utility of the SYNTAX score for risk stratification in ULMCAD is still 
controversial15-17. Capodanno et al. reported that PCI was associated with a higher mortality 
than CABG in ULMCAD patients with SYNTAX score >= 34 in 2 Italian centers15. In contrast, 
Kim et al. reported the SYNTAX score failed to stratify clinical outcome in patients with 
ULMCAD in a subanalysis of the MAIN-COMPARE study, although they demonstrated the 
utility of the SYNTAX score for risk stratification in patients who received DES16, 17. The 
current study provided additional support for the utility of the SYNTAX score for risk 
stratification in patients with ULMCAD. The results stratified by the SYNTAX tertiles in the 
current study were consistent with the results of the SYNTAX randomized trial5. Therefore, PCI 
for ULMCAD patients with high SYNTAX score should be discouraged unless the operative 
risk is prohibitively high. On the other hand, the long-term clinical outcome of PCI seemed to 
be comparable to that of CABG in patients with low or intermediate SYNTAX score, 
supporting recent trend for expanding use of PCI in this category of ULMCAD patients. 
However, the number of patients studied was still insufficient to advocate widespread use of 
PCI in ULMCAD patients with less complex coronary anatomy. The results of the EXCEL trial, 
which is an ongoing randomized trial comparing PCI using everolimus-eluting stents with 
CABG in 2600 ULMCAD patients with SYNTAX score <33, would provide further guidance 
for PCI use in this important subset of patients.   
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There are several important limitations in this study. First and most importantly, 
observational study design precluded definitive conclusions in terms of superiority of either PCI 
or CABG due to selection bias and unmeasured confounders. Since CABG had been considered 
to be the gold standard for ULMCAD patients, selection bias could be greater in patients with 
ULMCAD as compared with other subsets of severe coronary artery disease such as triple 
vessel coronary artery disease. Therefore, the results in the current study should be interpreted 
very carefully. Furthermore, the results from the SYNTAX subgroup analyses should be 
regarded as hypothesis generating. Second, number of patients enrolled was still small and 
SYNTAX score data were not available for all patients. Third, the duration of follow-up might 
not be sufficient to evaluate long-term outcome of coronary revascularization. Finally, we did 
not exclude those patients in whom PCI was not attempted for the left main coronary artery 
lesions based on clinical judgments. The current study population might include patients with 
less severe left main coronary artery lesions in both PCI and CABG groups.   
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Figure 1. Study flow-chart. 
AMI=acute myocardial infarction, CABG=coronary artery bypass grafting, 
CREDO-Kyoto=Coronary REvascularization Demonstrating Outcome study in Kyoto, 
PCI=percutaneous coronary intervention, SYNTAX=SYNergy between percutaneous coronary 
intervention with TAXus and cardiac surgery, and ULMCA=unprotected left main coronary 
artery. 
 
Figure 2. Kaplan-Meier event curves: PCI versus CABG for A) a composite of all-cause death, 
myocardial infarction and stroke, (B) all-cause death, (C) cardiac death, (D) stroke, (E) 
myocardial infarction, and (F) any revascularization. 
CABG=coronary artery bypass grafting, and PCI=percutaneous coronary intervention. 
 
Figure 3. Kaplan-Meier event curves comparing PCI with CABG for a composite of all-cause 
death, myocardial infarction and stroke stratified by SYNTAX score tertiles; (A) low SYNTAX 
score category (<23), (B) intermediate SYNTAX score category (23-33), and (C) high 
SYNTAX score category (≥33). 
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CABG=coronary artery bypass grafting, MI=myocardial infarction, PCI=percutaneous coronary 
intervention, and SYNTAX=SYNergy between percutaneous coronary intervention with TAXus 








Table 1: Comparison of Baseline Characteristics Between Percutaneous Coronary 
Intervention (PCI) and Coronary Artery Bypass Grafting (CABG) Groups 
 PCI (n=365) CABG (n=640) p value 
(A) Clinical characteristics     
Age (years) 71.4±10.1 69.4±9.2 0.001  
   Age >= 75 years*† 151 (41%) 208 (33%) 0.005  
Male* 259 (71%) 490 (77%) 0.051  
Body mass index (kg/m2) 23.4±3.4 23.2±3.0 0.35  
   Body mass index < 25.0 kg/m2* 271 (74%) 467 (73%) 0.66  
Unstable angina pectoris 52 (14%) 71 (11%) 0.15  
Hypertension* 313 (86%) 542 (85%) 0.65  
Diabetes mellitus* 155 (42%) 291 (45%) 0.36  
   on insulin therapy 35 (9.6%) 93 (15%) 0.02  
Current smoker* 79 (22%) 157 (25%) 0.30  
Heart failure*  76 (21%) 131 (20%) 0.89  
Ejection fraction (%) 59.3±14.7 60.2±13.4 0.34  
Ejection fraction <= 40% 34 (12%) 56 (9.5%) 0.30  
Mitral regurgitation grade 3/4 * 25 (6.9%) 17 (2.7%) 0.002  
Prior myocardial infarction* 70 (19%) 105 (16%) 0.27  
Prior Stroke (symptomatic)* 54 (15%) 75 (12%) 0.16  
Peripheral vascular disease* 45 (12%) 76 (12%) 0.83  
Estimated glomerular filtration rate 
(mL/min/1.73m2) 
62.2 (45.7-74.5) 61.0 (46.6-72.1) 0.20  
Estimated glomerular filtration rate <30  
mL/min/1.73m2,without hemodialysis*†
19 (5.2%) 38 (5.9%) 0.63  
Hemodialysis*† 26 (7.1%) 44 (6.9%) 0.88  
Anemia (Hb <11.0g/dl)* 72 (20%) 128 (20%) 0.92  
Platelet count <100×109/L* 3 (0.8%) 19 (3.0%) 0.02  
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Chronic obstructive pulmonary disease * 12 (3.3%) 17 (2.7%) 0.57  
Liver cirrhosis* 9 (2.5%) 19 (3.0%) 0.64  
Malignancy* 58 (16%) 69 (11%) 0.02  
(B) Procedural characteristics    
Number of target lesions or anastmoses 2.00±1.03 3.09±1.04 <0.0001 
Extent of coronary artery disease   <0.0001 
  Isolated ULMCA disease 31 (8.5%) 57 (8.9%)  
  ULMCA + 1 vessel disease 89 (24.4%) 108 (16.9%)  
  ULMCA + 2 vessel disease 132 (36.2%) 182 (28.4%)  
  ULMCA + 3 vessel disease 113 (31.0%) 293 (45.8%)  
Target of proximal LAD* 174 (48%) 451 (70%) <0.0001 
Target of Chronic total occlusion* 45 (12%) 166 (26%) <0.0001 
Emergency procedure 34 (9.3%) 50 (7.8%) 0.41  
SYNTAX score 26.5 (21-34) 30 (22-40) <0.0001 
  Low <23 123 (34.4%) 154 (26.8%)  
  Intermediate 23-33 131 (36.6%) 177 (30.8%) 0.0002 
  High >=33 104 (29.1%) 243 (42.3%)  
Total number of stents 2.78±1.70 ― ― 
Total stent length (mm) 58.7±41.0 ― ― 
Stent use 357 (98%) ― ― 
Drug-eluting stent use 277 (78%) ― ― 
Internal thoracic artery use ― 629 (98%) ― 
Off Pump ― 414 (65%) ― 
Baseline Medications     
  Antiplatelet therapy    
    Thienopyridine 362 (99%) 72 (11%) <0.0001 
       Ticlopidine 316 (87%) 67 (94%) 0.07  
       Clopidogrel 46 (13%) 4 (5.6%)  
    Aspirin 361 (99%) 632 (99%) 0.83  
    Cilostazol* 45 (12%) 41 (6.4%) 0.002  
  Other medications    
    Statins* 184 (50%) 199 (31%) <0.0001 
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Continuous variables are shown as mean ± SD or median (Interquartile range).  
* Risk adjusting variables selected for Cox proportional hazard models. 
†Risk adjusting variables selected for the multivariable models (parsimonious models for the subgroup 
analysis). 
 
    Beta-blockers* 110 (30%) 174 (27%) 0.32  
    Angiotensin converting enzyme  
inhibitor /Angiotensin receptor  
blocker* 
191 (52%) 211 (33%) <0.0001 
    Nitrates* 170 (47%) 230 (36%) 0.001  
    Calcium channel blockers* 171 (47%) 332 (52%) 0.13 
    Nicorandil* 94 (26%) 277 (43%) <0.0001 
    Warfarin* 30 (8.2%) 244 (38%) <0.0001 
    Proton pump inhibitors*† 92 (25%) 263 (41%) <0.0001 
    H2-blockers* 78 (21%) 204 (32%) 0.0003 
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Table 2: Univariate and Multivariate Analysis for 3-Year Clinical Outcomes: 
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting 
  
PCI  CABG  
Univariate  
HR (95% CI)  
p value 
Multivariate 
HR (95% CI)  
p value 
(n=365)  (n=640)  
N of events 
(Incidence) 
N of events 
(Incidence) 
Death/MI/Stroke 74 (22.7%) 84 (14.8%) 1.67 (1.24-2.24) 0.0006 1.30 (0.79-2.15) 0.30 
Death 45 (13.6%) 50 (9.2%) 1.61 (1.10-2.34) 0.01 0.79 (0.40-1.57) 0.50 
  Cardiac death 25 (7.4%) 21 (3.7%) 2.20 (1.26-3.86) 0.005 1.80 (0.64-5.09) 0.27 
MI 18 (5.5%) 13 (2.3%) 2.72 (1.38-5.51) 0.003 2.47 (0.81-7.54) 0.11 
Stroke 19 (6.6%) 31 (5.5%) 1.25 (0.72-2.12) 0.43 0.79 (0.30-2.08) 0.63 
Coronary 
revascularization 






Supplemental Text   
 
Definitions for Clinical Characteristics 
 Baseline clinical characteristics, such as prior myocardial infarction, heart failure, hypertension, 
current smoking, atrial fibrillation, chronic obstructive lung disease, liver cirrhosis and malignancy were 
regarded as present when these diagnoses were recorded in the hospital charts. Elderly patients were 
defined as those patients >=75 years of age. Unstable angina was defined as Braunwald classification type 
3. Diabetes was defined as treatment with oral hypoglycemic agents and/or insulin, prior clinical 
diagnosis of diabetes, glycated hemoglobin level >=6.5%, or blood glucose level >=200 mg/dl. Blood 
glucose test results in the acute phase of acute myocardial infarction were not used for the diagnosis of 
diabetes. Prior stroke included both ischemic and hemorrhagic stroke and was defined as stroke with 
neurological symptoms lasting >24 hours. Peripheral vascular disease was regarded to be present when 
carotid, aortic, or other peripheral vascular disease was being treated or scheduled for surgical or 
endovascular interventions. Left ventricular ejection fraction (LVEF) was measured either by contrast left 
ventriculography or echocardiography. Patients with LVEF <=40% were regarded as having left 
ventricular dysfunction. Renal function was expressed as estimated glomerular filtration rate calculated 
by the Modification of Diet in Renal Disease (MDRD) formula modified for Japanese patients1. Anemia 
was defined as blood hemoglobin level less than 11.0 g/dl. Thrombocytopenia was defined as platelet 
count <100*109/L. A bifurcation lesion was defined as a lesion requiring insertion of a guidewire into the 
side-branch. Baseline medications were regarded as present if prescribed during the index hospitalization. 
 
Reference  
1. Matsuo S, Imai E, Horio M, et al; Collaborators developing the Japanese equation for estimated GFR. 




Supplemental Appendix A: List of participating centers and investigators for the 
CREDO-Kyoto AMI Registry 
 
Cardiology 
Kyoto University Hospital: Takeshi Kimura 
Kishiwada City Hospital: Mitsuo Matsuda, Hirokazu Mitsuoka 
Tenri Hospital: Yoshihisa Nakagawa 
Hyogo Prefectural Amagasaki Hospital: Hisayoshi Fujiwara, Yoshiki Takatsu, Ryoji Taniguchi 
Kitano Hospital: Ryuji Nohara 
Koto Memorial Hospital: Tomoyuki Murakami, Teruki Takeda 
Kokura Memorial Hospital: Masakiyo Nobuyoshi, Masashi Iwabuchi 
Maizuru Kyosai Hospital: Ryozo Tatami 
Nara Hospital, Kinki University Faculty of Medicine: Manabu Shirotani 
Kobe City Medical Center General Hospital: Toru Kita, Yutaka Furukawa, Natsuhiko Ehara 
Nishi-Kobe Medical Center: Hiroshi Kato, Hiroshi Eizawa 
Kansai Denryoku Hospital: Katsuhisa Ishii 
Osaka Red Cross Hospital: Masaru Tanaka 
University of Fukui Hospital: Jong-Dae Lee, Akira Nakano 
Shizuoka City Shizuoka Hospital: Akinori Takizawa 
Hamamatsu Rosai Hospital: Masaaki Takahashi 
Shiga University of Medical Science Hospital: Minoru Horie, Hiroyuki Takashima 
Japanese Red Cross Wakayama Medical Center: Takashi Tamura 
Shimabara Hospital: Mamoru Takahashi 
Kagoshima University Medica and Dental Hospital: Chuwa Tei, Shuichi Hamasaki 
Shizuoka General Hospital: Hirofumi Kambara, Osamu Doi, Satoshi Kaburagi 
Kurashiki Central Hospital: Kazuaki Mitsudo, Kazushige Kadota 
Mitsubishi Kyoto Hospital: Shinji Miki, Tetsu Mizoguchi 
Kumamoto University Hospital: Hisao Ogawa, Seigo Sugiyama 
Shimada Municipal Hospital: Ryuichi Hattori, Takeshi Aoyama, Makoto Araki 
Juntendo University Shizuoka Hospital: Satoru Suwa 
 
Cardiovascular Surgery 
Kyoto University Hospital: Ryuzo Sakata, Tadashi Ikeda, Akira Marui 
Kishiwada City Hospital: Masahiko Onoe 
Tenri Hospital: Kazuo Yamanaka 
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Hyogo Prefectural Amagasaki Hospital: Keiichi Fujiwara, Nobuhisa Ohno 
Kokura Memorial Hospital: Michiya Hanyu 
Maizuru Kyosai Hospital:  Tsutomu Matsushita 
Nara Hospital, Kinki University Faculty of Medicine: Noboru Nishiwaki, Yuichi Yoshida 
Kobe City Medical Center General Hospital: Yukikatsu Okada, Michihiro Nasu 
Osaka Red Cross Hospital: Shogo Nakayama 
University of Fukui Hospital: Kuniyoshi Tanaka, Takaaki Koshiji, Koichi Morioka 
Shizuoka City Shizuoka Hospital: Mitsuomi Shimamoto, Fumio Yamazaki 
Hamamatsu Rosai Hospital: Junichiro Nishizawa 
Japanese Red Cross Wakayama Medical Center: Masaki Aota 
Shimabara Hospital: Takafumi Tabata 
Kagoshima University Medica and Dental Hospital: Yutaka Imoto, Hiroyuki Yamamoto 
Shizuoka General Hospital: Katsuhiko Matsuda, Masafumi Nara 
Kurashiki Central Hospital: Tatsuhiko Komiya 
Mitsubishi Kyoto Hospital: Hiroyuki Nakajima 
Kumamoto University Hospital: Michio Kawasuji, Syuji Moriyama 




Supplemental Appendix B: List of clinical research coordinators 
 
Research Institute for Production Development 
Kumiko Kitagawa, Misato Yamauchi, Naoko Okamoto, Yumika Fujino, Saori Tezuka, Asuka Saeki, 
Miya Hanazawa, Yuki Sato, Chikako Hibi, Hitomi Sasae, Emi Takinami, Yuriko Uchida, Yuko 
Yamamoto, Satoko Nishida, Mai Yoshimoto, Sachiko Maeda, Izumi Miki, Saeko Minematsu  
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Supplemental Appendix C: List of the SYNTAX score committee members 
 
Masao Imai (Kyoto University Hospital), Kyohei Yamaji (Kokura Memorial Hospital), Kazuya Nagao 
(Osaka Red Cross Hospital), Shunsuke Funakoshi (Kobe City Medical Center General Hospital), 
Natsuhiko Ehara (Kobe City Medical Center General Hospital), Koji Hanazawa (Tenri Hospital), Akihiro 
Tokushige (Kagoshima University Hospital), Tomohisa Tada (Deutsches Herzzentrum), Masahiro 
Natsuaki (Kyoto University Hospital), Junichi Tazaki (Kyoto University Hospital), Hiroki Shiomi (Kyoto 
University Hospital), Yoshihiro Kato (Saiseikai Noe Hospital), Mamoru Hayano (Gunma Cardiovascular 
Center), Syunichiro Niki (Hirakata Kohsai Hospital), Nobuya Higashitani (Kyoto University Hospital), 
Mitsuhiko Yahata (Kyoto University Hospital), Sayaka Saijo (Hyogo Prefectural Amagasaki Hospital), 
Yuichi Kawase (Japanese Red Cross Wakayama Medical Center). 
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Supplemental Appendix D: List of the clinical event committee members 
 
Mitsuru Abe (Kyoto Medical Center), Hiroki Shiomi (Kyoto University Hospital), Tomohisa Tada 
(Deutsches Herzzentrum), Junichi Tazaki (Kyoto University Hospital), Yoshihiro Kato (Saiseikai Noe 
Hospital), Mamoru Hayano (Gunma Cardiovascular Center), Akihiro Tokushige (Kagoshima University 
Hospital), Masahiro Natsuaki (Kyoto University Hospital), Tetsu Nakajima (Kyoto University Hospital). 
 
